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ABSTRACT 
 
A prospective analysis of active Human Cytomegalovirus infection (HCMV) was conducted on 33 
pediatric renal or hematopoietic stem cell post-transplant patients. The HCMV-DNA positive samples 
were evaluated for the prevalence of different gB subtypes and their subsequent correlation with clinical 
signs. The surveillance of HCMV active infection was based on the monitoring of antigenemia (AGM) 
and on a nested polymerase chain reaction (N-PCR) for the detection of HCMV in the patients studied. 
Using restriction analysis of the gB gene sequence by PCR-RFLP (Restriction Fragment Length 
Polymorphism), different HCMV strains could be detected and classified in at least four HCMV 
genotypes. Thirty-three pediatric recipients of renal or bone marrow transplantation were monitored. 
Twenty out of thirty-three (60.6%) patients demonstrated active HCMV infection. gB1 and gB2 
genotypes were more frequent in this population.  In this study, we observed that gB2 had correlation 
with reactivation of HCMV infection and that patients with mixture of genotypes did not show any 
symptoms of HCMV disease. Future studies has been made to confirm this.  
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INTRODUCTION 
 
Human cytomegalovirus (HCMV) remains the most 
important cause of serious viral infections in pediatric 
transplant recipients (23). In these patients, early diagnosis of 
active HCMV infection is important, since the development of 
HCMV disease may be prevented (17). Ganciclovir has been 
established as an effective treatment agent for infection by 
HCMV (15, 38). Primary HCMV infection occurs in patients 
that were HCMV-seronegative prior to acquiring HCMV. 
Recurrent infection occurs in patients that have previously 
documented infection with no virus detected for at least 4 
weeks during active surveillance; such infection may result 
from reactivation of latent virus or reinfection. HCMV disease 
can occur from infection acquired post-operatively in the 
transplanted organ or from reactivation of latent infection with 
symptoms and/or tissue invasion (25). The risk is highest 
within 2 months after transplantation. Several risk factors for  
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HCMV disease have been identified and include HCMV-
positive donor, HCMV-negative recipient, lack of antiviral 
prophylaxis, and receipt of cadaveric kidney or type of bone 
marrow transplant. Intense immunosuppression has also been 
implicated. Detection of HCMV DNA by qualitative PCR and 
of protein pp65 by antigenemia, together, are good methods for 
the detection of active infection.  The HCMV antigenemia 
assay is a rapid and semi-quantitative method that is widely 
used us a guideline for starting treatment therapy with 
ganciclovir (14). Genetic variability of genes among different 
virus strains may influence clinical manifestations of HCMV 
infections (19, 37). Such variability, particularly in the 
glycoprotein B (gB) gene of the viral envelope, appears to be 
of clinical relevance because these proteins are assumed to play 
an essential role in the induction of immune response and in 
viral entry into host cells, and have been considered as a 
potential marker for viral virulence (4, 6, 24). Since differences 
among gB strains may influence pathogenesis (19, 33), we 
examined the frequency distribution of gB, by monitoring 
active HCMV infection in pediatric patients recipients of renal 
and bone marrow transplants using HCMV-DNA detection and 
the antigenemia test. The subtype results were correlated with 
the clinical findings.   
 
MATERIALS AND METHODS 
 
Thirty-three patients (19 recipients of renal and 14 
recipients of bone marrow transplant) were monitored 
prospectively for active HCMV infection from August 2004 to 
December 2005 using AGM and N-PCR. The characteristics of 
the groups studied were described in Table 1. The patients 
were followed from day 0 until day 150 after the transplant. 
Blood was colleted weekly for AGM and N-PCR. The protocol 
was designed in accordance with the requirements for research 
involving human subjects in Brazil and approved by the 
Institutional Ethics Committee. The sample of the patients who 
were positive for the nested-PCR (10, 35) were selected for 
genotyping. 
 
 
Table 1. Characteristics of the groups studied 
Characteristic  BMT (n=14) Renal (n=19) 
Age-median in years (range) 10 (2-18) 11 (5-18) 
Sex -male/female 10/4 10/9 
Underlying disease-n (%) AML   
NHL  
SAA  
8 (57) 
3 (21.4) 
3 (21.4) 
CNS  
CHG 
UC 
16 (84.2) 
2 (10.5) 
1 (5.3) 
Donor type Allogeneic 14 (60.9) 
 
Cadaver  
Living 
related 
15 (78.9) 
4 (21.1) 
Pretransplant HCMV serostatus – n (%) 
IgG-HCMV- R-/D+ 
IgG-HCMV- R+/D+ 
 
- 
14 (100) 
 
2 (10.5) 
17 (89.5) 
Conditioning regimen - n (%) 
Bu+Cy 
Prograf/Micofenolat/Pred+Simulet 
 
14 (100) 
- 
 
- 
19 (100) 
HCMV prophylaxis  (Ganciclovir) - 2 (IgG-) 
BMT-Bone Marrow Transplantation; AML-Acute myelogenous leukemia; NHL-Non-Hodgkin lymphoma; SAA-severe anemia aplastic 
anemia; CNC-Congenital nephrotic syndrome; CHG-Chronic and hereditary glomerulonephritis; UC-Unknown cause; R-/D+-negative 
recipient with positive donor IgG-HCMV; R+/D+-positive recipient and donor for IgG-HCMV; Bu-busulfan; Cy-cyclosphosphamide; 
Pred-prednosone. 
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HCMV antigenemia (AGM) assay 
The antigenemia assay was performed at least once a week 
after engraftment, as previously described (34), with some 
modifications (5, 18, 29). Briefly, EDTA-treated blood samples 
were fractionated by dextran sedimentation followed by 
erythrocyte lysis. The granulocytes were then centrifuged to 
prepare Cytospin slides (3 X 105 granulocytes per slide). The 
slides were air-dried and fixed with formaldehyde, then 
immunostained with monoclonal antibodies, C10 and C11 
(Clonab HCMV; Biotest, Dreieich, Germany), and reacted with 
peroxidase-labeled anti-mouse cojugate (HRP, Biotest, 
Dreieich, Germany). The test was carried out in duplicate. 
 
Nested polymerase chain reaction (N-PCR) 
HCMV DNA in blood specimens was detected by nested 
PCR, using the primers described by Demmler et al (11) and 
Shibata et al (31). Briefly, leukocytes remaining from the 
HCMV antigenemia assay were lysed and the DNA was 
precipitated. The primers were selected from the MIE region of 
HCMV-AD169. The size of the PCR amplification products 
was 159 base pairs. The same protocol was used to amplify the 
human β-globin gene sequence to guarantee the quality of the 
extracted DNA. 
 
Treatment of active HCMV infection 
Patients with proven active HCMV infection received 
ganciclovir (5mg/Kg, i.v.) twice a day for 7 days, followed by 
a maintenance dose of 5 mg/Kg/day, i.v., 3 times a week. 
Treatment was restarted if active HCMV infection remained 
detectable. Treatment of HCMV disease was treated with 
ganciclovir (5 mg/Kg, i.v.), twice a day for 21 days, followed 
by a maintenance dose of 5 mg/Kg/day, i.v., three times a week 
for 4 weeks. 
 
Definitions 
Active HCMV infection was defined based on one or both 
of the following criteria: (1) one or more positive cells in the 
AGM assay, and (2) two or more consecutive positive N-PCR 
results. HCMV disease was defined as HCMV infection with 
specific signs or symptoms consistent with presumed or proven 
disease. A presumed case of HCMV disease was defined as 
demonstration of HCMV infection and fever of greater than 
38.8ºC for at least 2 days, and one of the following: atypical 
lymphocytosis; white blood cell count less than 4,000/mm3; or 
platelet count less than 100,000/mm3, without any other 
infection or non-infectious cause identified after investigations 
that included assays for EBV infection and other etiologies for 
post-transplant infections (25). Recurrence of HCMV infection 
or Disease was defined as active HCMV infection or HCMV 
disease occurring after negative N-PCR and/or AGM assays, 
following treatment of the initial episode of infection or 
disease. Late active HCMV infections and diseases were 
defined as those occurring more than 100 days after transplant 
(5). 
 
Amplification of the gB gene by nested PCR 
The oligonucleotide primers used for PCR amplification 
were chosen in a region of high sequence variability in the 
HCMV gB gene, as previously published (9, 35) and were 
synthetized commercially (Invitrogen, Life Technologies, SP, 
Brazil). Primers are listed in Table 2. The first and the second 
rounds of amplification were carried out in a total volume of 
50µl using 200 ng DNA extract (1st) and 1 µl PCR product 
(2nd) and 49 µl PCR mix (10 mM Tris pH 8.3, 50 mM KCl, 2 
mM MgCl2, 200 µM of each dNTPs, 1.25U of recombinant 
Taq DNA polymerase and 0.4 µM of each primer (Invitrogen, 
Life Technologies). After amplification, 5 µl of the amplified 
product were electrophoresed on 2% agarose gel (Gibco-BRL, 
Gand Island, NY) containing ethidium bromide, and the gel 
was photographed under UV illumination. The AD169 strain 
was used as a positive control; an uninfected DNA sample or 
water was used as a negative control. 
 
RFLP analysis 
Approximately 10 µl of nested PCR product were digested 
at 37oC overnight, using 1U of the restriction enzymes, Rsa I 
and Hinf I (Gibco-BRL). Sequences were analyzed on a 2% 
agarose 1000 gel (Gibco-BRL). The four types of gB were 
distinguished by their different patterns of fragment lengths, as 
described (9). 
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Table 2. gB Primers sequences and PCR product sizes 
Round Primer sequences 
Forward                                                            Reverse 
PCR product 
1st gB 1319 
TGGAACTGGAACGTTTGGC (22) 
gB 1659 
GCACCTTGACGCTGGTTTGG (9) 
~ 355 bp 
2 st gB 1319 
TGGAACTGGAACGTTTGGC (22) 
gB 1604 
GAAACGCGCGGCAATCGG (22) 
~ 299-305 bp 
 Note: All sequences are based on the AD 169 sequence (GenBank Accession No. X04606).  
 
 
 
RESULTS 
 
Active HCMV infection after transplantation 
Antigen pp65-HCMV and HCMV-DNA were successfully 
detected by AGM and N-PCR, respectively. Table 3 shows the 
incidence of active HCMV infection detected by AGM and/or 
N-PCR. Twenty out of thirty-three patients (60.6%) had active 
HCMV infection during monitoring, in a median of 41 days 
after the transplant. Five of these patients were BMT recipients 
(35.7%) with a median of 41 days after the transplant, and 
thirteen were renal recipients (79%) with a median of 42 days 
after the transplant. Two renal transplant patients were HCMV-
IgG negative prior to the transplant and had primary HCMV 
infection because the organ was from an HCMV-IgG positive 
donor. Both of these patients had active HCMV infection and 
presumptive disease, even though both had received 
ganciclovir prophylaxis after the transplant. Table 4 shows the 
correlation between antigenemia and N-PCR positive. Four 
patients had active HCMV infection detected by N-PCR and no 
detect by AGM. These cases did’nt show HCMV disease. 
 
Recurrence of active HCMV Infection 
Recurrence of active HCMV infection occurred in five out 
of twenty patients with previous active HCMV infection, in a 
median of 128 days after the transplant. These results are 
summarized in Table 3. 
 
 
Table 3. Incidence of active HCMV infection  
 BMT – n(%) 
N=14 
Renal – n(%) 
N=19 
Total – n (%) 
N=33 
Active HCMV infection Patients, n (%) 
median time-days (range) 
5 (35.7) 
41 (13-98) 
15 (79) 
42 (16-110) 
20 (60.6) 
41 (13-98) 
2 or more positive consecutive results by N-PCR (%) 
median time-days (range) 
5 (35.7) 
37 (13-98) 
15 (79) 
40 (16-110) 
20 (60.6) 
41 (13-110) 
1 or more positive cells by AGM (%)  
(range positive cells) 
median time-days (range) 
3 (21.4) 
(1-15) 
45 (13-98) 
13 (68.4) 
(1-80) 
44 (22-98) 
16 (48.5) 
(1-80) 
41 (13-110) 
Recurrence of active HCMV infection median time-days 
(range) (AGM and N-PCR simultaneously positive) 
1/5 (20) 
98 
4/15(26.7) 
128 (93-189) 
5/20 (25) 
128 (93-189) 
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Table 4. Relationship between AGM and N-PCR during follow-up of 33 patients after the transplant 
 
AGM/ 
N-PCR 
negative 
Only  
N-PCR 
positive 
N-PCR (+) 
before AGM 
(+) 
AGM and  
N-PCR simultaneously 
positive 
RENAL (n=19) 4 (21%) 2 (10.5%) 4 (21%) 9 (47.4%) 
BMT (n=14) 9 (64.3%) 2 (10.5%) 1 (7%) 2 (14.3%) 
Total (n=33) 13 (39.4%) 4 (12%) 5 (15%) 11 (33.3%) 
HCMVSymptoms - - - 9 (81.8%) 
 
 
HCMV disease 
Nine out of twenty patients with active HCMV infection 
(45%) developed presumptive HCMV disease. Two out of five 
(40%) of these patients were bone marrow recipients and seven 
out of fifteen (46.7%) were recipients of renal transplants, all 
of them received kidnies from a cadaveric donor. The most 
frequent symptoms in these patients were fever, diarrhea and 
vomiting. Patients with active HCMV infection, detected by 
AGM and/or N-PCR plus clinical symptoms, were considered 
presumptive HCMV disease.  
 
Recurrence of HCMV disease 
Recurrence of HCMV disease occurred in five out of nine 
patients (55.5%) with previous HCMV disease, in a median of 
128 days after the transplant. These results are summarized in 
Table 5.  
 
 
Table 5. Incidence of HCMV disease in patients with active HCMV infection. 
 BMT – n(%) 
N=14 
Renal – n(%) 
N=19 
Total – n (%) 
N=33 
Patients with active HCMV infection, n (%) 
median time-days (range) 
5 (35.7) 
41 (13-98) 
15 (79) 
42 (16-110) 
20 (60.6) 
41 (13-98) 
HCMV Disease (%) 
median time-days (range) 
2 (40%) 
41 (41-42) 
7 (46.7) 
49 (31-72) 
9 (45) 
42 (31-72) 
Recurrence of HCMV Disease or late HCMV disease 
median time-days (range) 
1/2 (50) 
98 
4/7(57) 
110 (98-198) 
5/9 (55.5) 
128 (98-198) 
 
 
Causes of death 
Four patients died (12.1%). Three of these died as a result 
of the BMT (21.4%). One death was the result of HCMV 
disease (interstitial pneumonia-IP), one was transplant-related 
and one due to other causes. The renal transplant recipient died 
due to graft-dysfunction. 
 
Relationship between AGM and N-PCR 
Table 4 shows the relationship between AGM and N-PCR 
during follow-up of 33 patients after transplant. Active HCMV 
infection detection occurred in 20 patients (60.6%). In 4 
patients (20%), only the N-PCR detected active HCMV 
infection, but no patient had manifestation of disease.  
 
Analysis of gB variation by N-PCR-RFLP 
In the HCMV-DNA positive samples of twenty patients 
with active HCMV infection and five HCMV-DNA positive 
samples of patients with recurrence of active HCMV infection 
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(total=25), nested polymerase chain reaction amplification was 
performed, using primers for the gB region. Restriction enzyme 
digestion of the HCMV gene was performed and resulted in 
four digestion patterns, as previously demonstrated (9).  The 
genotypes detected by PCR using primers gB1319 and gB1604 
are presented in Table 6. Genotypes found were: Nine HCMV-
DNA positive samples (45%) compatible with the gB1 
genotype. Five (25%) samples were compatible with gB2 and 
six patients were a mixture of gB genotypes. Coinfections with 
two different HCMV genotypes were frequently detected. Of 
the patients that demonstrated a mixture of gB types, 3 (12%) 
were compatible with the gB1 and gB2, genotypes two were 
gB1 and gB4 (8%) and one was gB2 and gB3 (4%). No gB3 
and gB4 genotypes were found alone in the patients studied; 
however, these genotypes were detected in gB mixtures.  
 
Prevalence of gB-HCMV subtypes and their correlation 
with clinical findings 
All patients that demonstrated the gB1 genotype had 
symptoms of the presumptive HCMV disease and were 
successfully treated with ganciclovir. All patients 
demonstrating the gB2 genotype presented more severe 
symptoms and HCMV reactivation after ganciclovir treatment. 
On the other hand, patients with a mixture of gB types did not 
demonstrate symptoms of HCMV disease and had a better 
prognostic.
 
Table 6 - Genotypes found in 25 HCMV-DNA positive samples and HCMV disease (active HCMV infection plus recurrence). 
Distribution of 
HCMV genotypes  
BMT – n (%) 
N=5 
Renal – n (%) 
N=15 
Total – n (%) 
N=20 
Patients with 
Episodes of HCMV 
Disease n(%) 
Glycoprotein type 1 
(gB1) 
1 (20) 8 (53.3) 9 (45) 9 (100) 
Glycoprotein type 2 
(gB2) 
1 (20)  4 (26.7) 5 (40) 5 (100) 
Glycoprotein type 3 
(gB3) 
- - - - 
Glycoprotein type 4 
(gB4) 
- - - - 
Mixed gB1 + gB2 1 (20) 2 (13.3) 3 (15) - 
Mixed gB1 + gB4 1 (20) 1 (6.7) 2 (10) - 
Mixed gB2 + gB3 1 (20) - 1 (5) - 
 
 
DISCUSSION 
 
This study was performed in a group of children who 
underwent bone marrow or renal transplant and was the first to 
be performed in Brazil. HCMV is the most important cause of 
disease occurring after renal or bone marrow transplantation. In 
renal transplant patients, HCMV is associated with an 
increased risk of rejection and, in BMT, HCMV infection often 
causes severe morbidity and may even cause death, particularly 
during the first 3 months after allogeneic SCT (27, 28). 
Specific studies on children are lacking, and the majority of 
data are derived from studies performed in adults (8). 
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Several techniques are currently available for the early 
detection of CMV, including quantitative PCR, (16) the 
detection of mRNA (13) and a hybrid capture assay (20). These 
techniques have not yet been adequately compared to others 
that are currently available (26).  
Two techniques for HCMV detection were used in this 
study, on a Nested PCR in leukocytes and antigenemia. 
Yaghobi et al, in 2005, showed the prognostic value of a 
double primer PCR assay to detect human cytomegalovirus 
(HCMV) infection or disease in bone marrow transplant 
(BMT) recipients (41). To discriminate between latent and 
active HCMV infection, blood samples were also tested by a 
quantitative antigenemia assay and compare with a double 
primer PCR assay and there was a good association between 
these tests for detection of active HCMV infection in all 
patients. Detection of HCMV-DNA in PMN leukocytes of 
BMT patients by double primer PCR assay can be an 
alternative method for antigenemia assay in leukopenic BMT 
recipients (41). In some of our cases, N-PCR detected active 
HCMV infection earlier than AGM, but in most of detections, 
AGM and N-PCR were detected simultaneously, according to 
our previous study (5).  
Xue W et al, in 2009, evaluate the diagnostic value of 
CMV-PCR and CMV-pp65 antigenemia for active HCMV 
monitoring infection after renal transplantation. The sensitivity 
and specificity of these two combined detection methods for 
CMV infection were high for the diagnosis of CMV infection. 
CMV-pp65 and CMV-PCR combined together provide an 
effective method to monitor CMV infection and predict its 
outcome (40). 
The incidence of active HCMV infection in our 33 
children, with a median of 11- years old (range 2-18), was 
60.6%. Fourteen were allogeneic bone marrow transplant 
recipients and nineteen were renal transplant recipients. 
Our results show that the incidence of HCMV infections in 
renal transplant recipients was 79% and HCMV disease was 
46.7%. This occurred within 2 months of transplantation. Rates 
of HCMV infection after renal transplant have been reportedly 
as high as 75% and the incidence of HCMV disease is between 
5 and 30% (3). 
In our study, the patients with HCMV disease were not 
proven.  Proof of HCMV disease is difficult due to the need for 
more invasive methods. Nevertheless, the data from this 
hypothesis-generating study suggest transplant characteristics 
associated with HCMV disease that, in turn, can be targeted for 
further studies likely to yield feasible prevention strategies. In 
our study, the patients with presumptive HCMV disease were 
treated successfully. 
The patients with active HCMV infections who were 
HCMV positive by Nested PCR had their DNA samples 
submitted to HCMV genotyping, according with publications 
(2, 9, 10, 12, 33, 36). The most frequently found genotypes 
were gB1 and gB2 (13). The genotypes gB3 and gB4 were 
found mixed with gB1 and gB2. The main clinical findings of 
presumptive HCMV disease in these patients were fewer, and 
occurred only in patients with the gB1 genotype. In patients 
with the gB2 genotype, the symptoms were more serious, such 
as diarrhea, abdominal pain and vomiting (presumptive HCMV 
gastrointestinal disease). With the mixture of genotypes, no 
symptoms occurred. This finding is in accordance with Woo et 
al., 1997 (39), who showed that HCMV gB type 2 is more 
frequent in BMT recipients with HCMV disease. 
Zhou et al, in 2007 showed that genetic variability within 
the gB genes occurs frequently (43). In a previous study, in 
Canada (21), of 50 solid organ transplant recipients with CMV 
disease, the following distribution of gB was observed: gB1, 
19/50 (38%); gB2, 9/50 (18%); gB3, 12/50 (24%), gB4, 2/50 
(4%), and mixed genotype infection was 16%. 
The study done by Carraro and Granato, in 2003, 
demonstrated that the presence of several gB strains in any 
given patient is most likely not due to primary infection by 
several strains but is more likely due to consecutive new 
infections by strains of different gB (7). 
Several risk factors for disease have been identified and 
include: HCMV-positive donors, HCMV-negative recipients, 
lack of anti-viral prophylaxis, and receipt of a cadaveric kidney 
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(27, 42). Intense immunosuppression has also been implicated 
(42). Pediatric renal transplant recipients, by virtue of their age, 
are more likely to have a combination of donor-
positive/recipient-negative grafts. They receive more 
immunosuppression and generally have a higher incidence of 
other viral infections.  
The risk of development of HCMV disease was most 
strongly correlated with transplantation using a kidney from a 
HCMV-seropositive donor, particularly when the recipient was 
sero negative. This finding is consistent with two previous 
pediatric studies, which showed that transplantation from a 
HCMV-seropositive donor was strongly correlated with 
HCMV disease in the seronegative recipient (22, 27) and these 
findings also suggest that, in pediatric patients, primary 
infection due to transplants from donors with HCMV infection 
may be more important than the re-activation of already 
established infections related to intense imunossupression (16). 
In conclusion, this study indicated that active HCMV 
infection detected by Nested-PCR and antigenemia together 
can be good methods for monitoring active HCMV infection 
and gB types 1 and 2 are more prevalent in our patients with 
HCMV disease. However, this study is limited because of the 
small patient number, thus making it difficult to draw a firm 
conclusion about the distribution of HCMV genotypes and 
their possible association with different types of patients and 
diseases. Nevertheless, these results may be taken as a 
preliminary report on the prevalence of different HCMV gB 
genotypes in Brazilian pediatric renal and bone marrow 
transplantation patients with active HCMV infection.   
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